StockData
Scotts Miracle-Gro Co logo

Scotts Miracle-Gro Co (SMG) stock analysis

SMGNYSEAgricultural ChemicalsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026Score 12/3024% above fair value
$63.74−1.30 (-2.00%)

Close on Nov 12, 2026Market cap $3.71BP/E 52.7Yield 4.14%

StockData Score

Prices as of Nov 12, 2026How the score works

Value2Growth3Performance3Health1Dividend3

Mixed12 of 30 checks passed

Scotts Miracle-Gro passes 12 of the 30 checks behind our score; 7 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
2/6
Growth
3/6
Past performance
3/6
Financial health
1/6
Dividend
3/6

What stands out

  • Return on capital over 10%

    Return on invested capital was 12.3%, above the 10% that usually covers the cost of capital.

  • Guidance raised

    Scotts Miracle-Gro raised its Full-Year Fiscal 2026 non-GAAP adjusted diluted net income per share from continuing operations outlook on Jul 29, 2026.

  • Covered by free cash flow

    Dividends take 58.6% of free cash flow.

  • EV/EBITDA below its 5-year median

    Scotts Miracle-Gro's EV/EBITDA of 15.2 is below its 5-year median of 15.8.

What to watch

  • Margin of safety under 20%

    The price is 23.5% above fair value, so there is no margin of safety.

  • Trading above fair value

    The share price of $63.74 is above our fair value estimate of $51.60.

  • Earnings shrank over 5 years

    Net income shrank 17.8% a year on average over the last five fiscal years.

  • Revenue growing under 10% a year

    Revenue grew -4.5% a year over the last three fiscal years, short of the 10% we look for.

Valuation2/6
  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E above the industry

    Scotts Miracle-Gro's P/E of 52.7 is above the Chemicals and Allied Products median of 25.0.

  • EV/EBITDA below its 5-year median

    Scotts Miracle-Gro's EV/EBITDA of 15.2 is below its 5-year median of 15.8.

  • P/S below the industry

    Scotts Miracle-Gro's price-to-sales of 1.07 is below the Chemicals and Allied Products median of 3.27 (book value is negative, so we use sales).

  • Trading above fair value

    The share price of $63.74 is above our fair value estimate of $51.60.

  • Margin of safety under 20%

    The price is 23.5% above fair value, so there is no margin of safety.

Growth3/6
  • Revenue growing under 10% a year

    Revenue grew -4.5% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing faster than the industry

    Revenue grew 4.6% over the last twelve months; the Chemicals and Allied Products median is 4.6%.

  • Guidance raised

    Scotts Miracle-Gro raised its Full-Year Fiscal 2026 non-GAAP adjusted diluted net income per share from continuing operations outlook on Jul 29, 2026.

  • Gross margin improving

    Gross margin was 31.8% over the last twelve months, against 29.2% a year earlier.

Past performance3/6
  • Return on equity

    Needs positive equity and five years of results.

  • Return on capital over 10%

    Return on invested capital was 12.3%, above the 10% that usually covers the cost of capital.

  • Return on equity against the industry

    Needs positive equity.

  • Earnings shrank over 5 years

    Net income shrank 17.8% a year on average over the last five fiscal years.

  • Net margin above its 5-year average

    Net margin was 2.1% over the last twelve months, against a 5-year average of -1.6%.

  • Net margin above the industry

    Scotts Miracle-Gro's net margin of 2.1% is above the Chemicals and Allied Products median of -9.4%.

Financial health1/6
  • Debt level

    Needs debt and equity figures.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals 17.5% of total debt; we look for at least 20%.

  • Interest not well covered

    Operating income covers interest expense 3.4 times; we look for at least 5.

  • Short-term assets cover short-term debts

    Current assets are 1.21 times current liabilities.

  • Bankruptcy risk in the grey zone

    The Altman Z-score is 2.43; above 3 is the safe zone and below 1.8 the distress zone.

Dividend3/6
  • Pays a dividend

    Scotts Miracle-Gro paid dividends worth 4.1% of the share price over the last twelve months.

  • Yield below Treasuries

    The 4.1% yield is below the 4.6% on a 1-year Treasury.

  • Yield in the top quarter

    The top quarter of US dividend payers yield 3.9% or more; Scotts Miracle-Gro yields 4.1%.

  • Dividend was cut

    The dividend per share fell by more than 10% at least once in the last 10 fiscal years.

  • Not covered by earnings

    Dividends take 209% of net income, leaving little room.

  • Covered by free cash flow

    Dividends take 58.6% of free cash flow.

Scores of similar companies

Our estimate per share

$51.60

The share price is 24% above this estimate.

20%+ below
Near fair value
20%+ above
$63.74Price$51.60Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/E25.0×–25.0×$30.2244%
EV/EBITDA16.2×15.8×16.5×$70.2939%
Earnings power11.4% cost of equity––$65.0217%
Fair value$51.60100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Chemicals and Allied Products median 25.0

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$65.86M
Value traded per 1% price move
$34.93M

Downside

Medium risk

Typical loss in a bad month
16.7%
Volatility (annualized)
40%
Sharpe ratio, 1 year
0.14
Beta to the S&P 500 (5Y)
1.29

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Gross margin

30.6%−2.0 pts over 5 years

Operating margin

10.5%−3.7 pts over 5 years

Net margin

4.3%−5.1 pts over 5 years

See a number that looks wrong?